These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26175405)

  • 21. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness.
    Gao X; Jin W
    Cancer Lett; 2014 Oct; 353(1):25-31. PubMed ID: 25042866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy.
    Mischel PS; Nelson SF; Cloughesy TF
    Cancer Biol Ther; 2003; 2(3):242-7. PubMed ID: 12878856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal diversity in glioblastoma: is it clinically relevant?
    Watts C; Piccirillo SG
    Future Oncol; 2015; 11(12):1703-6. PubMed ID: 26075436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance.
    Noch EK; Ramakrishna R; Magge R
    World Neurosurg; 2018 Aug; 116():505-517. PubMed ID: 30049045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI study identifies three subtypes of glioblastoma.
    Brower V
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized targeted therapy for glioblastoma: fact or fiction?
    Weller M; Stupp R; Hegi M; Wick W
    Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
    Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO
    J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice.
    Jackson PR; Juliano J; Hawkins-Daarud A; Rockne RC; Swanson KR
    Bull Math Biol; 2015 May; 77(5):846-56. PubMed ID: 25795318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy.
    Archavlis E; Tselis N; Birn G; Ulrich P; Zamboglou N
    Neurol Res; 2014 Dec; 36(12):1047-55. PubMed ID: 24852696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological spectrum in recurrences of glioblastoma multiforme.
    Marucci G; Fabbri PV; Morandi L; De Biase D; Di Oto E; Tallini G; Sturiale C; Franceschi E; Frezza GP; Foschini MP
    Pathologica; 2015 Mar; 107(1):1-8. PubMed ID: 26591624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges.
    Nicholas MK; Lukas RV; Chmura S; Yamini B; Lesniak M; Pytel P
    Semin Oncol; 2011 Apr; 38(2):243-53. PubMed ID: 21421114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular predictors in glioblastoma: toward personalized therapy.
    Colman H; Aldape K
    Arch Neurol; 2008 Jul; 65(7):877-83. PubMed ID: 18625854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epigenetic regulation in glioblastomas].
    Quillien V
    Ann Pathol; 2009 Nov; 29 Spec No 1():S34-6. PubMed ID: 19887247
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.